The U.S. Food and Drug Administration (FDA) today announced action to make it faster and less costly to develop biosimilar medicines, which are lower-cost alternatives to expensive biologic drugs used ...
Add Yahoo as a preferred source to see more of our stories on Google. The FDA has introduced a new draft guidance The US Food and Drug Administration (FDA) has debuted new draft guidance that aims to ...
How LC and MALS provide orthogonal, fit-for-purpose methods to assess critical quality attributes and reduce uncertainty How ...
The global unit will be headed by Armin Metzger, who will join Sandoz on April 1, 2026. Metzger, who will be president of biosimilar development, manufacturing and supply, joins Sandoz from ...
The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...
Biosimilars have yet to achieve their main purpose: to reduce the costs of complex biological drugs, as generics do for small molecules. Multiple barriers, from development costs to the contracting ...
The FDA has proposed new policies to speed up the development and lower the cost of biosimilar agents for cancer and other serious illnesses. These policies include “major updates to simplify ...
The first asset will be a vedolizumab biosimilar to Entyvio used to treat adult patients with Crohn’s disease, ulcerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results